

CATALYST PHARMACEUTICAL PARTNERS, INC.
Form 8-K
June 03, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of Earliest Event Reported): May 30, 2013

CATALYST PHARMACEUTICAL PARTNERS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

Delaware
(State or other jurisdiction

001-33057
(Commission File

76-0837053
(I.R.S. Employer

of incorporation)

Number)

Identification No.)

355 Alhambra Circle

Suite 1500

Coral Gables, Florida
(Address of principal executive offices)

33134
(Zip Code)

Registrant's telephone number, including area code:

(305) 529-2522

Not Applicable

Former Name or Former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K

“ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

“ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07 Submission of Matters to a Vote of Security Holders

On May 30, 2013, Catalyst Pharmaceutical Partners, Inc. (the Company) held its Annual Meeting of Stockholders at the Hyatt Regency Coral Gables, 50 Alhambra Plaza, Coral Gables, Florida. The final voting results on the matters considered at the meeting are as follows:

1. Election of Directors:

| Name | Votes For | Votes Withheld | Broker Non-Votes |
|--------------------|------------------|-----------------------|-------------------------|
| Patrick J. McEnany | 17,855,170 | 263,730 | 15,151,838 |
| Philip H. Coelho | 17,822,170 | 296,730 | 15,151,838 |
| Hubert E. Huckel | 17,800,055 | 318,845 | 15,151,838 |
| Charles B. O'Keefe | 17,852,216 | 266,684 | 15,151,838 |
| David S. Tierney | 17,855,770 | 263,130 | 15,151,838 |

2. Approval, on an advisory basis, of the compensation of the Company's named executive officers:

| Votes For | Votes Against | Votes Abstained | Broker Non-Votes |
|------------------|----------------------|------------------------|-------------------------|
| 17,604,563 | 420,034 | 94,303 | 15,151,838 |

3. Selection, on an advisory basis, of the frequency of "say-on-pay" votes:

| One Year | Two Years | Three Years | Abstain | Broker Non-Votes |
|-----------------|------------------|--------------------|----------------|-------------------------|
| 11,366,380 | 281,389 | 6,178,514 | 292,617 | 15,151,838 |

4. Ratification of the selection of Grant Thornton, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2013:

| Votes For | Votes Against | Votes Abstained |
|------------------|----------------------|------------------------|
| 33,043,182 | 153,011 | 74,545 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Catalyst Pharmaceutical Partners, Inc.

By: /s/ Alicia Grande
Alicia Grande

Vice President, Treasurer and Chief

Financial Officer

Dated: June 3, 2013